Halothane-induced hepatitis: A forgotten issue in developing countries

Peiman Habibollahi, Nastaran Mahboobi, Sara Esmaeili, Saeid Safari, Ali Dabbagh, Seyed Moayed Alavian

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Halothane was introduced as an anesthetic in the 1950s and was considered a revolutionary agent in the field of anesthesia. Soon after, halothane-induced hepatitis became a concern, leading to the development of less toxic gases that induced a lower incidence of side effects. Two types of halothane- related hepatotoxicity have been described: type 1, or mild hepatitis, is associated with elevated transaminase levels and self-limiting symptoms, and type 2, or severe hepatotoxicity, is associated with acute fatal liver failure and is fatal in most cases. Hepatotoxicity is most likely to be immunerelated, based on much evidence. Free radicals that are produced by the metabolism of halothane in the liver can modify cellular proteins and introduce neo-antigens to the immune system. Sensitization to these neo-antigens induces a more severe response after multiple exposures; most cases of type 2 hepatitis occur after repeated contact. New halogenated anesthetics such as enflurane, sevoflurane, and desflurane, are not metabolized in the liver, causing few cases of sensitization. Compared with halothane, these anesthetics are expensive. As a result, replacement of halothane with new halogenated anesthetics requires a precise cost-benefit analysis, especially in developing countries that have low health care budgets.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalHepatitis Monthly
Volume11
Issue number1
StatePublished - Jan 1 2011

    Fingerprint

Keywords

  • Anesthetics
  • Halogenated
  • Halothane
  • Hepatitis

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Habibollahi, P., Mahboobi, N., Esmaeili, S., Safari, S., Dabbagh, A., & Alavian, S. M. (2011). Halothane-induced hepatitis: A forgotten issue in developing countries. Hepatitis Monthly, 11(1), 3-6.